Logo Image
Business
Practice ManagementMalpractice ConsultHealth Law & Policy
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference ListingConference Previews Conference Recaps
Publications
Urology Times JournalEditorial Advisory BoardUrologists in Cancer CareSupplements and Featured PublicationsClinical Forums Recaps
More
CME/CE
Resources
Begin Your Journey: Tackling BurnoutSponsored MediaLive EventsInteractive ToolsJob BoardPartnersSponsored ResourcesTreatment Landscape Evolutions

Subscribe

  • Business
  • Watch
  • Conferences
  • Publications
  • CME/CE
  • Resources
  • Subscribe
  • Benign Conditions
  • Benign Prostatic Hyperplasia
  • Bladder Cancer
  • Female Urology
  • Genitourinary Cancers
  • Genomic Testing
  • Hormone Therapy
  • Kidney Cancer
  • Kidney Stones
    • Challenging Anatomy
  • Men's Health
  • Next-Generation Imaging
  • OAB and Incontinence
    • Voiding Dysfunction
  • Pediatrics
  • Prostate Cancer
    • Controveries in Urologic Cancer
    • Drug Therapy
  • Sexual Dysfunction
  • UTUC
  • Urologic Surgery
    • Cosmetic Surgery
Spotlight -
Peer Exchange|
Peers and Perspectives|
Case-Based Peer Perspectives|
Urology Times Journal
Advertisement

Mark T. Fleming, MD

Advertisement

Articles by Mark T. Fleming, MD

Mark Fleming, MD, and Manoj Bupathi, MD, discuss the most anticipated GU data at ASCO 2026

ByManojkumar Bupathi, MD, MS,Mark T. Fleming, MD
May 30th 2026

Mark Fleming, MD, and Manoj Bupathi, MD, MS, highlight the key studies and sessions in GU oncology that they're most anticipating at ASCO 2026.

Advertisement

Latest Updated Articles

  • Mark Fleming, MD, and Manoj Bupathi, MD, discuss the most anticipated GU data at ASCO 2026
    Mark Fleming, MD, and Manoj Bupathi, MD, discuss the most anticipated GU data at ASCO 2026

    May 30th 2026



Advertisement
Advertisement

Trending on Urology Times

1

Treating MIBC as a systemic disease reshapes bladder preservation

2

Durvalumab plus BCG may best serve patients with high-grade T1 NMIBC

3

William Huang, MD, discusses the potential of histotripsy for renal tumors

4

DASL-HiCaP Interim Results in Very High-Risk Localized Prostate Cancer

5

Alicia Morgans, MD, discusses cognitive outcomes with darolutamide vs enzalutamide

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Job Board
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us